000			03789na a2200577 4500
999			_c2461 _d2461
003			PC2461
005			20191129120621.0
008			130622s2013 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aMendiola Fernández, César _91804 _eOncología Médica
245	0	0	_aFluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study. _h[artículo]
260			_c2013 _bJournal of clinical oncology: official journal of the American Society of Clinical Oncology,
300			_a31(20):2593-9.
500			_aFormato Vancouver: Martín M, Ruiz A, Ruiz Borrego M, Barnadas A, González S, Calvo L, et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study. J Clin Oncol. 2013;31(20):2593–259.
501			_aPMID: 23733779
504			_aContiene 21 referencias
520			_aAdding taxanes to anthracycline-based adjuvant therapy improves survival outcomes of patients with node-positive breast cancer (BC). Currently, however, most patients with BC are node negative at diagnosis. The only pure node-negative study (Spanish Breast Cancer Research Group 9805) reported so far showed a docetaxel benefit but significant toxicity. Here we tested the efficacy and safety of weekly paclitaxel (wP) in node-negative patients, which is yet to be established.
710			_9303 _aServicio de Oncología Médica
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/2/pc2461.pdf _ySolicitar documento
942			_n0 _2ddc _cART